Waters Corporation

Zacks reviews Waters’ Q1 2026 results, highlighting a 91.5% year-on-year revenue jump to 1.27 billion dollars and a 20% increase in adjusted EPS to 2.70, driven by double-digit organic growth and early contributions from the BD Biosciences and Diagnostic Solutions acquisition. The note emphasizes stronger pharma and diagnostics demand, improved pricing discipline, and raised 2026 guidance, but keeps a Hold stance as integration execution, China exposure, and margin pressure temper the otherwise solid fundamental outlook.

This short research-style piece notes that WAT shares jumped 11.1% after Q1 2026 revenue of 1.27 billion dollars and adjusted EPS of 2.70 both beat consensus, with growth supported by organic performance and the BD acquisition. Citing Jefferies’ Tycho Peterson, it frames the quarter as a “solid proof point” that helps clear skepticism around the deal and underscores a higher 2026 revenue and EPS outlook, while pointing out the stock remains down year-to-date, implying room for sentiment normalization.

This deep-dive earnings note analyzes Waters’ Q4 2025, where revenue met expectations at 932.4 million dollars and adjusted EPS of 4.53 was in line, but the stock sold off on underperformance in the newly acquired BD Biosciences and Diagnostic Solutions unit and compressed operating margins. The report lays out a balanced thesis: it highlights chemistry and consumables strength, the long-term upside from subscription software and BD synergies, and targeted cost and pricing initiatives, while stressing integration risk, China weakness, and near-term margin headwinds as key issues to monitor.

This long-form equity analysis profiles Waters as it doubles in scale via the 17.5 billion dollar acquisition of BD’s Biosciences and Diagnostic Solutions business, detailing its razor-and-blade business model, roughly 67% recurring revenue mix, and exposure to structural growth drivers like PFAS testing, GLP-1 drug manufacturing, and biologics characterization. The author argues the combination of high recurring cash flows, leading positions in regulated analytical workflows, and synergy potential from BD positions WAT as a “durable innovation” story with attractive long-term upside, while explicitly flagging integration execution, elevated leverage, and China macro/geopolitical risk as the main overhangs.

This SEC-filing–based analysis summarizes Waters’ 8-K around its 2025 results and 2026 guidance, noting 2025 sales of 3.17 billion dollars and non-GAAP EPS of 13.13 alongside guidance for 2026 revenue of roughly 6.41–6.46 billion dollars and non-GAAP EPS of 14.30–14.50 driven by the BD Biosciences and Diagnostic Solutions combination. It frames the BD deal as transformative for scale and recurring revenue while highlighting the trade-off between strong non-GAAP growth and a sharp drop in GAAP EPS due to acquisition-related amortization, emphasizing that value realization hinges on synergy delivery and investors’ comfort with heavy reliance on adjusted metrics.